Literature DB >> 22923275

Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project.

Gregory Y H Lip1, Amitava Banerjee, Isabelle Lagrenade, Deirdre A Lane, Sophie Taillandier, Laurent Fauchier.   

Abstract

BACKGROUND: Management decisions for thromboprophylaxis in atrial fibrillation need to balance the risk of stroke against serious hemorrhage. The objective of the present analysis is to compare the Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly (HAS-BLED) score against other older bleeding risk scores and the new Anticoagulation and Risk Factors in Atrial Fibrillation score in an atrial fibrillation cohort. METHODS AND
RESULTS: Patients diagnosed with nonvalvular atrial fibrillation in a 4-hospital institution between 2000 and 2010 were identified. Independent risk factors of bleeding were investigated using Cox regression. The predictive value of several bleeding risk schema was assessed using the c-statistic and net reclassification improvement. Oral anticoagulation use was highest in moderate-risk patients (59.8%) but only slightly more than high-risk (50.1%) and low-risk (46.4%) patients. Those at higher bleeding risk (HAS-BLED ≥ 3) were also at highest risk of stroke/thromboembolism or stroke/thromboembolism/death, as well as bleeding and all-cause mortality. On multivariable analysis, independent predictors of bleeding were age ≥ 75 years and age ≥ 65 years, alcohol excess, anemia, and heart failure. All risk scores had only modest predictive ability for bleeding, whether on vitamin K antagonist or not (c-statistic ≈0.6). When the HAS-BLED score was compared with other bleeding risk scores, the net reclassification improvement was significantly improved against all other scores tested.
CONCLUSIONS: Current oral anticoagulation prescribing patterns would suggest that bleeding risk estimation by clinicians is poor and that oral anticoagulation prescribing does not reflect bleeding risk per se. The HAS-BLED score performs well in relation to predicting bleeding events compared with older bleeding scores and the Anticoagulation and Risk Factors in Atrial Fibrillation score, with significantly improved reclassification using HAS-BLED compared with all other bleeding risk scores tested.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22923275     DOI: 10.1161/CIRCEP.112.972869

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  20 in total

1.  Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation.

Authors:  Benjamin A Steinberg; Melissa A Greiner; Bradley G Hammill; Lesley H Curtis; Emelia J Benjamin; Susan R Heckbert; Jonathan P Piccini
Journal:  Cardiovasc Ther       Date:  2015-08       Impact factor: 3.023

2.  Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting.

Authors:  Joshua A Roth; Katharine Bradley; Kenneth E Thummel; David L Veenstra; Denise Boudreau
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-04-08       Impact factor: 2.890

Review 3.  Anemia: An Independent Predictor Of Adverse Outcomes In Older Patients With Atrial Fibrillation.

Authors:  Ali N Ali; Nandkishor V Athavale; Ahmed H Abdelhafiz
Journal:  J Atr Fibrillation       Date:  2016-04-30

Review 4.  Atrial fibrillation in the elderly.

Authors:  Teerapat Nantsupawat; Kenneth Nugent; Arintaya Phrommintikul
Journal:  Drugs Aging       Date:  2013-08       Impact factor: 3.923

Review 5.  Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making.

Authors:  Yishen Wang; Beata Bajorek
Journal:  Ther Adv Drug Saf       Date:  2014-02

Review 6.  Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis.

Authors:  Daniel Caldeira; João Costa; Ricardo M Fernandes; Fausto J Pinto; Joaquim J Ferreira
Journal:  J Interv Card Electrophysiol       Date:  2014-07-11       Impact factor: 1.900

Review 7.  Bleeding risk prediction models in atrial fibrillation.

Authors:  Isac C Thomas; Matthew J Sorrentino
Journal:  Curr Cardiol Rep       Date:  2014-01       Impact factor: 2.931

Review 8.  Stroke And Bleeding Risk Assessment: Where Are We Now?

Authors:  Mikhail S Dzeshka; Gregory Y H Lip
Journal:  J Atr Fibrillation       Date:  2014-04-30

9.  Predicting major bleeding in patients with noncardioembolic stroke on antiplatelets: S2TOP-BLEED.

Authors:  Nina A Hilkens; Ale Algra; Hans-Christoph Diener; Johannes B Reitsma; Philip M Bath; Laszlo Csiba; Werner Hacke; L Jaap Kappelle; Peter J Koudstaal; Didier Leys; Jean-Louis Mas; Ralph L Sacco; Pierre Amarenco; Leila Sissani; Jacoba P Greving
Journal:  Neurology       Date:  2017-08-02       Impact factor: 9.910

10.  Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review.

Authors:  Ethan D Borre; Adam Goode; Giselle Raitz; Bimal Shah; Angela Lowenstern; Ranee Chatterjee; Lauren Sharan; Nancy M Allen LaPointe; Roshini Yapa; J Kelly Davis; Kathryn Lallinger; Robyn Schmidt; Andrzej Kosinski; Sana M Al-Khatib; Gillian D Sanders
Journal:  Thromb Haemost       Date:  2018-10-30       Impact factor: 6.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.